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Abstract
Objective: Diet-induced obesity (DIO) leads to an accumulation of intra-myocardial lipid metabolites implicated in causing
cardiac insulin resistance and contractile dysfunction. One such metabolite is ceramide, and our aim was to determine the
effects of inhibiting de novo ceramide synthesis on cardiac function and insulin stimulated glucose utilization in mice
subjected to DIO.
Materials and Methods: C57BL/6 mice were fed a low fat diet or subjected to DIO for 12 weeks, and then treated for 4
weeks with either vehicle control or the serine palmitoyl transferase I (SPT I) inhibitor, myriocin. In vivo cardiac function was
assessed via ultrasound echocardiography, while glucose metabolism was assessed in isolated working hearts.
Results: DIO was not associated with an accumulation of intra-myocardial ceramide, but rather, an accumulation of
intra-myocardial DAG (2.6360.41 vs. 4.8060.97 nmol/g dry weight). Nonetheless, treatment of DIO mice with myriocin
decreased intra-myocardial ceramide levels (50.367.7 vs. 26.962.7 nmol/g dry weight) and prevented the DIO-
associated increase in intra-myocardial DAG levels. Interestingly, although DIO impaired myocardial glycolysis rates
(778961267 vs. 26716326 nmol/min/g dry weight), hearts from myriocin treated DIO mice exhibited an increase in
glycolysis rates.
Conclusions: Our data reveal that although intra-myocardial ceramide does not accumulate following DIO, inhibition of de
novo ceramide synthesis nonetheless reduces intra-myocardial ceramide levels and prevents the accumulation of intra-
myocardial DAG. These effects improved the DIO-associated impairment of cardiac glycolysis rates, suggesting that SPT I
inhibition increases cardiac glucose utilization.
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Introduction
Obesity, insulin resistance, and diabetes are rapidly increasing
in our society [1,2,3,4], and by 2025 it is estimated that more than
300 million individuals between 20 and 79 years of age will suffer
from diabetes [5]. Patients who suffer from these conditions often
possess a multitude of other pathologies, including hyperlipidemia
and hypertension. This set of risk factors is often referred to as the
‘‘Metabolic Syndrome’’ and increases one’s risk of cardiovascular
disease, the leading cause of mortality amongst patients in the
diabetic population [1]. Thus, therapeutic strategies aimed at
alleviating these conditions have the potential to reduce the
burden of cardiovascular disease.
As mentioned, obesity, insulin resistance, and diabetes are often
accompanied by a hyperlipidemia, which manifests itself in the
form of an elevation in plasma free fatty acids (FFAs). While there
is no argument that elevated plasma FFAs lead to increased rates
of fatty acid uptake in the heart, controversy remains as to how this
fatty acid overload contributes to cardiac dysfunction. It has been
postulated that an impaired ability of the heart to oxidize this fatty
acid surplus leads to an accumulation of intra-myocardial fatty
acid metabolites, such as triacylglycerol (TAG), long chain acyl
CoA, ceramide, and diacylglyerol (DAG), which contribute to the
development of contractile dysfunction, a term coined ‘‘cardiac
lipotoxicity’’ [1,6,7,8,9].
Supporting this proposal, recent findings in the obese Zucker rat
demonstrate that cardiac dysfunction is associated with reduced
rates of myocardial fatty acid oxidation compared to lean controls
during fasting, an effect accompanied by elevated levels of intra-
myocardial lipid and an inability to increase the expression of
peroxisome proliferator activated receptor a (PPARa) target genes
[1]. Conversely, our results show no difference in the rates of
myocardial fatty acid oxidation between insulin resistant JCR:LA-
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conditions [10]. Furthermore, insulin resistant JCR:LA-cp rats
showed nearly a doubling in intra-myocardial TAG, suggesting
that the accumulation of intra-myocardial fatty acid metabolites is
the result of an excessive fatty acid supply, rather than impaired
fatty acid oxidation. In addition, we have demonstrated that
myocardial fatty acid oxidation rates are increased in transgenic
PPARa overexpressing mice, a strain possessing a phenotype
resembling that of type 2 diabetes [11]. More recently, we have
shown in malonyl CoA decarboxylase deficient mice, a genetic
model of reduced fatty acid oxidation rates, a clear disconnect
between intra-myocardial TAG levels, insulin sensitivity and
cardiac function [12].
Therefore, debate still exists with regards to how the hyperlip-
idemia observed during obesity, insulin resistance, and diabetes
contributes to cardiac lipotoxicity and cardiac dysfunction. As
recent work has suggested that an elevation in intra-myocardial
ceramide levels may cause lipotoxicity by increasing rates of
apoptosis in the heart [13,14,15], we investigated this controversy
by examining the effect of inhibiting de novo ceramide synthesis
following diet-induced obesity (DIO) and insulin resistance. This
was achieved by feeding mice either a low or high fat diet rich in
saturated fat, which plays a major role in de novo ceramide synthesis
through serine palmitoyl transferase I (SPT I). A pharmacological
inhibitor of SPT I was utilized to determine if reducing intra-
myocardial ceramide levels could prevent cardiac lipotoxicity and
improve myocardial insulin sensitivity. We hypothesized that
pharmacological inhibition of de novo ceramide synthesis would
restore glucose utilization in the insulin-resistant heart and
improve cardiac function, implicating ceramide as an important
mediator responsible for cardiac lipotoxicity observed in obesity
and type 2 diabetes.
Materials and Methods
Animal Studies
The University of Alberta adheres to the principles for
biomedical research involving animals developed by the Council
for International Organizations of Medical Sciences and
complies with the Canadian Council on Animal Care guide-
lines. All animal procedures were approved by the University of
Alberta Health Sciences Animal Welfare Committee. 8-week old
C57BL/6 wild type mice (Charles River) were placed on a
standard chow/low fat diet (4% kcal from lard) or high fat diet
(60% kcal from lard, Research Diets; D12492) to produce diet-
induced obesity (DIO) over a 12-week period. At the end of
week 12, animals were treated every other day with the SPT I
inhibitor, myriocin (0.5 mg/kg), via intraperitoneal injection for
a 4-week period. At the end of the treatment period, animals
were sacrificed (12 mg sodium pentobarbital) in the fed state
during the dark cycle, and the hearts were subsequently
removed and perfused in the working mode as described below.
In another study, 6-week-old db/db mice and their heterozygous
controls (db/+) (Jackson Laboratories) were placed on an
identical 4-week treatment regimen.
Isolated Working Heart Perfusions
Immediately after animal sacrifice, hearts were excised and
cannulated via the aorta and left atrium. After equilibration in the
Langendorff mode, hearts were switched to the working mode and
perfused with modified Krebs-Henseleit buffer (KHB) containing
118.5 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 5 mM [5-
3H]/
[U-
14C]glucose, 1.2 mM palmitate pre-bound to 3% fatty acid
free bovine serum albumin, and 100 mU/mL insulin. Hearts
underwent aerobic perfusion for 40 min and rates of glycolysis and
glucose oxidation were measured by quantitative collection of
3H2O and
14CO2, respectively, as previously described [16,17]. At
the end of the 40 min aerobic perfusion protocol, hearts were
immediately frozen in liquid N2 and stored at 280uC until used
for biochemical analyses.
Calculation of Proton (H
+) Production from Glucose
Utilization
H
+ production attributable to glucose metabolism was calcu-
lated from the measured rates of glycolysis and glucose oxidation.
If the rate of glycolysis exceeds subsequent glucose oxidation, a net
production of two H
+s per molecule of glucose occurs [18,19].
Thus, overall rates of H
+ production derived from glucose
utilization were determined by subtracting the rate of glucose
oxidation from the rate of glycolysis and multiplying by two.
In vivo Cardiac Function via Echocardiography
In vivo cardiac function (ejection fraction, fractional shorten-
ing) and M-mode ventricular wall measurements (left ventricular
wall thickness and diameters) were assessed in isoflurane
anaesthetized mice with a Vevo 770 high-resolution echocardi-
ography imaging system equipped with a 30-MHz transducer
(RMV-707B; VisualSonics, Toronto, Canada) as previously
described [20].
Intra-myocardial Fatty Acid Metabolite Determination
Extraction and quantification of long chain acyl CoA and short
chain acyl CoA esters via high performance liquid chromatogra-
phy (HPLC) were performed as previously described [10,21].
TAGs were extracted with a 2:1 chloroform-methanol solution
and quantified with a commercially available enzymatic assay kit
(Wako Pure Chemical Industries) as previously described [10].
Ceramides were extracted via HPLC, and DAGs were extracted
via thin layer chromatography (TLC) as previously described [22].
In brief, myocardial tissue was extracted for ceramide with 1 mL
of a 1:1:1 chloroform-methanol-1 N HCl in the presence of
0.3 mL saline solution. The resulting organic phase was separated
and dried under N2. 0.5 mL of 1 M KOH in 90% (v/v) methanol
was added and samples were heated at 90uC for 1 hr to deacylate
ceramide into sphingosine. Samples are then extracted with 1 M
HCl in methanol, chloroform, and 1 M aqueous NaCl. The
resulting organic phase was dried under N2, re-dissolved in
methanol, and derivatized to o-Phthalaldehyde to generate a
fluorescent compound that was separated by HPLC and
quantified by fluorescence spectrometry. With regards to DAG,
,5 mg of myocardial tissue was homogenized in 0.8 ml of 1 mM
NaCl. The homogenate was then transferred over to a 13 x
100 mm test tube and extracted with 3.0 ml of 1:2 chloroform-
methanol and mixed. 1 ml of 1 mM NaCl and chloroform was
then added to break phases and the resulting sample was
centrifuged briefly at 5,000 xg to separate the organic and aqueous
phases. The chloroform phase was then collected and evaporated
under N2 gas. The lipids were then solubilized with a 7.5% octyl-
b-D-glucoside/5mM cardiolipin/1mM DETAPAC solution and
incubated at room temperature for 5 to 15 min. The sample was
then brought to 100 ml volume with 50 ml of 2x reaction buffer,
20 ml 10 mM DTT and 10 ml DAG kinase (0.5 mg/ml). The
reaction was initiated by the addition of 10 ml of 10 mM ATP
(mixed with [c-
32P]ATP) and incubated for 30 min at 25uC. 3 mL
chloroform/methanol (1:2) and 0.7 mL 1% HClO4 was then
added to each tube and mixed before the addition of 1 mL
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separated via centrifugation at 2,000 xg at 4uC for 5 min. The
aqueous phase was discarded and the chloroform phase washed
twice with 2 ml of 1% HClO4. The sample was then evaporated
under N2 gas and dissolved in 100 ml of 5% methanol in
chloroform. 20 ml of each sample was spotted onto a TLC plate
followed by activation with acetone (develop with choloroform/
methanol/acetic acid (65:15:5)). After TLC plate has ran, the plate
was exposed to X-ray film and developed for ,48 hrs. Finally, the
silicon was scraped off the plate into 5 ml scintillation vials with
4 ml of scintillation solution (Ecolite, ICN) and
32P counted in a
liquid scintillation counter.
Pyruvate Dehydrogenase (PDH) Activity
PDH activities were measured using a revised protocol based on
the radiometric assay described by Constantin-Teodosiu et al. [23],
and as previously described [12]. Briefly, for measurement of
active PDH, frozen myocardial tissue (,20 mg) was homogenized
in buffer containing 200 mM sucrose, 50 mM KCl, 5 mM EGTA,
50 mM Tris HCl, 50 mM NaF, 50 mM sodium pyrophosphate
(NaPPi), 5 mM dicholoroacetate, and 0.1% Triton X-100
(pH 7.8). For assay of ‘‘total’’ PDH activity (dephosphorylated),
frozen tissue was homogenized in buffer containing 1 mM CaCl2
but in the absence of NaF, NaPPi, and EGTA. Samples were
neutralized and centrifuged, and the resulting supernatant was
used for determination of acetyl-CoA content. Acetyl CoA was
converted to [
14C]citrate and separated from unreacted radioac-
tivity using Dowex resin (50WX8, 100–200 mesh). The amount of
acetyl CoA was determined by comparison of acetyl CoA standard
curves ran in parallel during the experiment.
Hydroxyacyl CoA Dehydrogenase Activity
Frozen ventricular tissue (5–10 mg) was homogenized in buffer
containing 50 mM Tris HCl (pH 8 at 4uC), 1 mM EDTA, 10%
glycerol (w/v), 0.02% Brij-35 (w/v), 1 mM DTT, protease and
phosphatase inhibitors (Sigma). After homogenization for 30 sec,
the homogenate was left on ice for 10 min before centrifugation at
10,000 x g for 20 min. The resulting supernatant was brought to a
final dilution of 1/20, and 10 mL of each sample was pipetted into
a 96 well plate. Each well was brought to a final volume of 190 mL
with 160 mL of 50 mM imidazole (pH 7.4) and 20 mL of 1.5 mM
NADH. The reaction was then initiated by the addition of 10 mL
of 2 mM acetoacetyl CoA and the reaction mixture has its
absorbance followed at a 340 nM wavelength for a 5 min duration
(readings taken in 30 sec intervals) with a spectrophotometer
kinetic plate reader. The 96 well plate was read at a 340 nM
wavelength for a 5 min duration as well before the addition of
acetoacetyl CoA in order to obtain a baseline reading. The final
reading was multiplied by 60 to obtain a rate per min, and
hydroxyacyl CoA Dehydrogenase activity in ‘‘mmol/min/g wet
weight’’ was calculated with the following equation:
(DAbsorbance340=min|0:2mL(volumeof reaction))=
(6:22(eforNADHdisappearance)|0:552(pathlength
for96wellplate)|0:4(mgof tissueinreaction))
Immunoblot Analysis
Immunoblots were carried out to determine protein expression
and phosphorylation in hearts as previously described [24]. In
brief, frozen ventricular tissue (25–30 mg) was homogenized in
buffer containing 50 mM Tris HCl (pH 8 at 4uC), 1 mM EDTA,
10% glycerol (wt/vol), 0.02% Brij-35 (wt/vol), 1 mM dithiothre-
itol, protease and phosphatase inhibitors (Sigma). After homoge-
nization for 30 s, the homogenate was left on ice for 10 min before
centrifugation at 10 000 x g for 20 min. The resulting supernatant
was processed for immunoblotting. Protein concentration of
homogenates was determined via Bradford protein assay kit
(Bio-Rad). Samples were resolved via 8% sodium didecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto a 0.45 mm nitrocellulose membrane. Membranes were
blocked with 10% fat free milk for 2 hours and probed with
either anti-AMPK (Cell Signaling Technologies, 1/1000 dilution),
anti-phosphoThreonine-172 AMPK (Cell Signaling Technologies,
1/500 dilution), anti-Akt (Cell Signaling Technologies, 1/1000
dilution), anti-phosphoSerine-473 Akt (Cell Signaling Technolo-
gies, 1/500 dilution), anti-GSK3b (Cell Signaling Technologies,
1/1000 dilution), anti-phosphoSerine-9 GSK3b (Cell Signaling
Technologies, 1/500 dilution), anti-acetyl CoA carboxylase (ACC,
Jackson ImmunoResearch Laboratories, 1/1000 dilution), anti-
peroxisome proliferator activated receptor alpha (PPARa, Abcam,
1/1000 dilution), anti-CD36 (Santa Cruz Biotechnology, 1/1500
dilution), anti-uncoupling protein 3 (UCP3, Alpha Diagnostic, 1/
2000 dilution), and anti-pyruvate dehydrogenase kinase 4 (PDK4,
Abgent, 1/200 dilution) antibodies in 5% fatty acid free bovine
serum albumin. Immunoblots were visualized with the enhanced
chemiluminescence Western blot detection kit (Perkin Elmer) and
quantified with Quantity One (4.4.0) Software (Biorad Laborato-
ries).
Statistical Analyses
All values are presented as mean 6 SE (n observations). The
significance of differences was determined by the use of an
unpaired, two-tailed Student’s t-test or one-way analysis of
variance (ANOVA), followed by Bonferroni’s post-hoc analysis
where appropriate. Differences were considered significant when
P,0.05.
Results
Diet-induced Obesity and Subsequent Insulin Resistance
do not Cause Cardiac Dysfunction
Following 12 weeks of high fat feeding, animals became severely
obese and insulin resistant (Figure 1). Interestingly, this was not
accompanied by any cardiac dysfunction or hypertrophy as
determined via ultrasound echocardiography (Table 1). Similar
results were obtained when hearts were aerobically perfused in the
working mode for a 40 min period after 16 weeks of high fat
feeding (Table 2).
Diet-induced Obesity and Insulin Resistance Reduce
Myocardial Glycolysis Rates, Which are Restored by
Myriocin Treatment
Aerobic perfusion of hearts following DIO showed a marked
reduction in myocardial glycolysis rates, and a strong trend
towards a reduction in glucose oxidation rates (Figure 2). However
treatment with the SPT I inhibitor, myriocin (0.5 mg/kg), every
other day for 4 weeks increased myocardial glycolysis rates in DIO
mice compared to control treated DIO mice (Figure 2A). In
addition, a trend to increased myocardial glucose oxidation rates
was observed in DIO myriocin treated mice (Figure 2B). Further
support for this was evident by the fact that myocardial PDH
activity was reduced by DIO in the control treated mice, but not in
the myriocin treated mice (Figure 3A/B). Moreover, protein
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and subsequently inhibiting PDH, was increased in DIO control
treated mice versus their lean counterparts, but not in the DIO
myriocin treated mice versus their lean counterparts (Figure 3C).
Interestingly, we observed a small trend to an increased
H
+ production from uncoupled glucose metabolism in hearts
from DIO mice treated with myriocin (Figure 4).
Myriocin Treatment does not Affect Malonyl CoA
Content or Fatty Acid Oxidation Protein Expression
Following Diet-induced Obesity and Insulin Resistance
Although rates of myocardial fatty acid oxidation were not
measured in this study, levels of malonyl CoA, a major
determinant of fatty acid oxidation rates [25,26], were not altered
by either high fat feeding or myriocin treatment, suggesting that
fatty acid oxidation rates were not different between groups
(Table 3). Furthermore, protein expression of PPARa or its
downstream targets, UCP3 and CD36, were similar in hearts from
control and myriocin treated DIO mice, as was the expression of
ACC (Figure 5A–D), the key enzyme involved in the generation of
malonyl CoA. No change in the activity of the mitochondrial fatty
acid oxidation enzyme, hydroxyacyl CoA dehydrogenase, was
observed in hearts from control and myriocin treated DIO mice
(Figure 5E). Plasma fatty acid delivery to the heart can also
regulate myocardial fatty acid oxidation rates, and measurement
of plasma lipids demonstrated no difference in circulating fatty
acids between DIO control and myriocin treated mice, though a
trend to reduced circulating TAGs was observed in myriocin
treated mice (Table 4).
Figure 1. Insulin resistance in mice following DIO. A: 12 weeks of
DIO results in significant increases in body weight in mice. B: This
increase in body weight resulted in whole body glucose intolerance,
and C: insulin resistance. Values represent mean 6 SE (n=10–11).
Glucose and insulin were administered via intraperitoneal injection.
Differences were determined using an unpaired Student’s two-tailed t-
test or two-way ANOVA followed by a Bonferroni’s post-hoc analysis.
*P,0.05, significantly different from low fat fed counterpart.
{P,0.05,
significantly different from low fat fed counterpart at 12 weeks post-
diet.
doi:10.1371/journal.pone.0037703.g001
Table 1. In vivo cardiac function and left ventricular wall
measurements in lean and DIO mice treated with myriocin.
Study
Group
Lean
Control
(n=4)
Lean
Myriocin
(n=5)
DIO
Control
(n=5)
DIO
Myriocin
(n=6)
EF (%) 62.964.1 64.261.5 59.262.5 58.762.3
FS (%) 33.862.8 34.561.1 31.361.7 30.861.5
IVSd (mm) 0.8360.02 0.7860.01 0.8660.03 0.8460.02
LVIDd (mm) 4.1660.14 3.9760.05 4.3060.09 4.2460.15
LVPWd (mm) 0.7860.02 0.7760.03 0.8360.03 0.8360.02
IVSs (mm) 1.2060.04 1.1460.04 1.2860.03 1.2260.04
LVIDs (mm) 2.7660.20 2.6060.07 2.9660.11 2.9460.15
LVPWs (mm) 1.2160.03 1.1860.02 1.2460.06 1.2260.05
In vivo cardiac function and ventricular wall measurements were assessed via
echocardiography in isoflurane anesthetized lean or DIO mice treated with
vehicle control or myriocin. Values represent means 6 SE. *P,0.05, indicates a
significant difference from control treated mice. LVPW=left ventricular
posterior wall, LVID=left ventricular internal diameter, IVS=intraventricular
septum, d=diastole, s=systole.
doi:10.1371/journal.pone.0037703.t001
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Following Diet-induced Obesity and Insulin Resistance
In parallel to the restoration of myocardial glycolysis rates, we
observed increased phorphorylation of Akt at serine 473, which is
indicative of Akt activity, in hearts from DIO mice treated with
myriocin compared to vehicle control (Figure 6A). However,
phosphorylation of downstream targets of Akt, such as glycogen
synthase kinase 3 (GSK3) only demonstrated a trend to an increase
in DIO mice treated with myriocin compared to vehicle control
(Figure 6B).
Myriocin Treatment Leads to a Marked Reduction in
Intra-myocardial Ceramide Levels and Prevents the Diet-
induced Obesity Associated Increase in DAG Levels
Similar to what we have reported in previous studies [12], DIO
does not increase myocardial TAG levels (Figure 7A). Nonetheless,
as expected, inhibition of de novo ceramide synthesis at the level of
SPT I via myriocin treatment markedly reduced intra-myocardial
ceramide levels (Figure 7B). Surprisingly, DIO per se did not
actually increase intra-myocardial ceramide levels (Figure 7B),
mimicking our previous findings [12,27]. In contrast to our
previous studies [12,27], we did not observe an increase in intra-
myocardial long chain acyl CoAs following DIO (Figure 7C).
However, this likely arises from the high palmitate concentration
used in the perfusate (1.2 mM), which would arbitrarily increase
the long chain acyl CoA levels in perfused hearts from low fat fed
animals. Interestingly, DIO increased DAG levels in hearts from
control treated mice, and although there was no difference in
DAG levels in hearts from myriocin treated DIO mice, DIO did
not increase intra-myocardial DAG levels in myriocin treated mice
versus their low fat fed counterparts (Figure 7D).
Myriocin Treatment has no Effect on Cardiac Function
or Insulin Signaling in Obese Leptin Receptor Deficient
db/db Mice
In another set of experiments, obese and insulin resistant db/db
mice, and their heterozygous controls (db/+), were placed on a
myriocin treatment regimen identical to the DIO mice. Treatment
of db/db mice with myriocin decreased intra-myocardial ceramide
content, but had no effect on DAG content (Figure 8). Although
myriocin treatment prevented the development of insulin
resistance and improved skeletal muscle insulin signaling in db/
db mice cardiac insulin signaling itself was not impaired in db/db
versus db/+ mice (data not shown). As such, myriocin treatment
had no effect on insulin stimulated myocardial Akt, GSK3, or
AMPK phosphorylation in db/db mice (Figure 6D), but interest-
ingly, did show a strong trend to a reduction in myocardial PDK4
expression (P=0.06, Figure 4D). As PDK4 negatively regulates
PDH activity, and db/db mice have reduced myocardial glucose
oxidation rates [28,29], this suggests the possibility that despite
myriocin treatment having no effect on insulin signaling in db/db
mice, it may improve myocardial glucose utilization at the level of
oxidation, similar to what is observed in myriocin treated DIO
mice. PDK4 expression/activity is increased in response to
PPARa and/or enhanced fatty acid oxidation [11]. Measurement
of PPARa and its downstream target genes, UCP3 and CD36,
revealed a general trend to reduced PPARa signaling in db/db
Table 2. Ex vivo cardiac function in lean and obese mice
treated with myriocin.
Study
Group
Lean
Control
(n=7)
Lean
Myriocin
(n=7)
DIO
Control
(n=6)
DIO
Myriocin
(n=7)
Heart Rate
(beats per minute)
269.9616.4 284.4619.3 262.1610.2 246.4611.2
Cardiac Output
(mL/min)
12.560.4 11.061.0 10.960.4 9.260.6
Cardiac Work
(mL*mmHg/min)
8.260.4 7.260.8 7.660.3 7.060.5
Parameters of cardiac function were assessed in isolated working hearts
obtained from mice subjected to either a low fat or high fat diet and treated
with vehicle control or myriocin (n=6–7). Values represent means 6 SE.
doi:10.1371/journal.pone.0037703.t002
Figure 2. SPT I inhibition improves myocardial glycolysis rates in DIO mice. A: DIO impairs insulin-stimulated glycolysis rates in hearts from
control treated mice, which was improved in hearts from myriocin treated DIO mice. B: Rates of glucose oxidation in hearts from control and myriocin
treated low fat fed and DIO mice. Values represent mean 6 SE (n=6–7). Differences were determined using a one-way ANOVA followed by a
Bonferroni’s post-hoc analysis. *P,0.05, significantly different from low fat fed counterpart.
{P,0.05, significantly different from DIO control.
doi:10.1371/journal.pone.0037703.g002
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circulating TAGs was also observed in db/db myriocin treated
mice (Table 4). This suggests that reduced plasma lipid delivery
and subsequent PPARa activity is responsible for the decline in
PDK4 expression. Despite these potential metabolic changes,
there were no differences in hydroxyacyl CoA dehydrogenase
activity between hearts from control and myriocin treated db/db
mice (Figure 9E), while cardiac function was not impaired in db/db
mice, and myriocin treatment did not alter function or left
ventricular wall measurements (Table 5).
Discussion
We report in this study that while DIO itself per se does not
elevate intra-myocardial ceramide levels, inhibition of SPT I to
prevent de novo synthesis of ceramide results in a marked reduction
in overall intra-myocardial ceramide levels, and improves the
DIO-associated reduction in myocardial glycolysis rates. Such
findings yield provocative insights into the role of obesity on
cardiac lipotoxicity and function. It has been proposed that during
states of obesity, the accumulation of lipid metabolites in the heart
such as TAG, long chain acyl CoA, DAG, and ceramide results in
contractile dysfunction and contributes to the development of
cardiomyopathy [14,30]. Ceramide, in particular, is believed to
play a major role in the development of cardiac lipotoxicity, as its
accumulation has been shown in a number of in vitro and in vivo
models to cause apoptosis of cardiac myocytes, which itself would
contribute to the contractile dysfunction associated with cardiac
lipotoxicity [13,14,15,31,32].
In contrast, our findings suggest that DIO does not result in
ceramide accumulation in the heart, suggesting that perhaps the
ceramide-induced apoptosis, which contributes to cardiac dys-
function, is the result of extreme situations induced by transgene
overexpression [13,14]. Nonetheless, the ceramide/sphingolipid
pool is under dynamic regulation, being influenced by both its
Figure 3. Cardiac PDH activity is not impaired in DIO mice
treated with myriocin. A: Cardiac PDH activity in control and
myriocin treated DIO Mice. B: % decrease in cardiac PDH activity relative
to low fat fed counterparts. C: Cardiac PDK4 protein expression is
increased in control treated DIO mice, but not myriocin treated DIO
mice. Values represent mean 6 SE (n=6). Differences were determined
using an unpaired Student’s two-tailed t-test or a one-way ANOVA
followed by a Bonferroni’s post-hoc analysis. *P,0.05, significantly
different from DIO control mice.
{P,0.05, significantly different from
low fat fed counterpart.
doi:10.1371/journal.pone.0037703.g003
Figure 4. H
+ production in hearts from DIO mice. H
+ production
was calculated in control and myriocin treated DIO mice by subtracting
the rate of glucose oxidation from the rate of glycolysis and multiplying
by two. Values represent mean 6 SE (n=6–7). Differences were
determined using an unpaired Student’s two-tailed t-test. *P=0.13.
doi:10.1371/journal.pone.0037703.g004
Ceramide and Myocardial Glucose Metabolism
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37703rates of synthesis and degradation [15]. It is possible that enzymes
involved in ceramide degradation were also upregulated by DIO,
thereby masking any increase in its synthesis. Studies in humans
support this possibility, as the mRNA expression of ceramide
metabolizing/degrading enzymes such as ceramidase and sphin-
gosine kinase is increased in right atrial appendages of obese
humans with and without a history of type 2 diabetes, explaining
why intra-myocardial ceramide content was similar to lean
humans despite an elevation in SPT I mRNA expression [33].
Furthermore, our measurement of overall intra-myocardial
ceramide content does not separate ceramide originating from
de novo synthesis via SPT I versus that originating from phospho-
lipid hydrolysis.
Our findings differ slightly from a recent study by Park TS et
al., who demonstrated that cardiac-specific overexpression of
glycosylphosphatidylinositol anchored human lipoprotein lipase
in mice is associated with cardiac dysfunction and elevated
levels of intra-myocardial ceramide [14]. However, treatment of
these animals with myriocin prevented intra-myocardial cer-
amide accumulation, restored glucose oxidation, and restored
cardiac function. Although we also observed improved glucose
metabolism in our DIO mice treated with myriocin, we did not
Table 3. Cardiac malonyl CoA levels (nmol/g dry weight).
Study Group
Lean
Control
Lean
Myriocin
DIO
Control DIO Myriocin
Malonyl CoA 4.4660.72 5.7761.17 6.9661.02 9.4962.31
Cardiac malonyl CoA content was measured in WT mice fed a low or high fat
diet and treated with vehicle control or myriocin (n=5–6). Values represent
means 6 SE.
doi:10.1371/journal.pone.0037703.t003
Figure 5. Expression of enzymes involved in the regulation of fatty acid oxidation and hydroxyacyl CoA dehydrogenase activity in
DIO mice. Protein expression of A: PPARa, B: UCP3, C: CD36, and D: ACC in hearts from control and myriocin treated DIO mice. E: Hydroxyacyl CoA
dehydrogenase activity was similar in ventricular homogenates from control and myriocin treated DIO mice. Values represent mean 6 SE (n=5–7).
doi:10.1371/journal.pone.0037703.g005
Table 4. Plasma Lipids in DIO and db/db mice.
Study
Group
DIO
Control
DIO
Myriocin
db/db
Control
db/db
Myriocin
TAG (mg/dL) 53611 34662 4 4 642 165626
FFA (mM) 0.4460.05 0.4860.06 0.7160.09 0.7060.06
Plasma TAG and FFA levels ad libitum were measured in DIO and db/db mice
treated with vehicle control or myriocin (n=4–7). Values represent means 6 SE.
doi:10.1371/journal.pone.0037703.t004
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our high fat diet model did not result in cardiac dysfunction
because intra-myocardial ceramides did not accumulate. A
recent study in middle-aged mice (40–44 weeks) has shown that
ceramides do accumulate in the heart following a 12-week
high fat feeding regimen [34]. However, systolic cardiac
function was not altered, suggesting that an elevation of
ceramide content in the heart may not negatively impact
Figure 6. Cardiac Akt phosphorylation in increased in myriocin treated DIO mice. Isolated working mouse hearts were perfused
aerobically in the presence of insulin (100 mU/mL ) for determination of, A: Cardiac Akt serine 473 phosphorylation, B: GSK3b serine 9
phosphorylation, and C: AMPK threonine 172 phosphorylation in low fat fed and DIO mice treated with control or myriocin D: Cardiac Akt serine 473
phosphorylation, GSK3b serine 9 phosphorylation, AMPK threonine 172 phosphorylation, and PDK4 expression in control and myriocin treated db/db
mouse hearts. Values represent mean 6 SE (n=4–7). Differences were determined using an unpaired Student’s two-tailed t-test or a one-way ANOVA
followed by Bonferroni post-hoc analysis. *P,0.05, significantly different from DIO control treated mice.
{P=0.06.
doi:10.1371/journal.pone.0037703.g006
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investigating the time points required for DIO in mice to induce
cardiac dysfunction, and whether manipulation of SPT 1 and
ceramide content in the heart can improve this deficit.
In our model, DIO did not result in a rise in intra-
myocardial TAG content. While such findings may seem
unexpected, we have previously shown that in C57BL/6 mice,
intra-myocardial TAG content initially increases following 3
weeks of DIO, but reverts to normal levels seen in lean mice at
10 weeks of DIO, due to a decrease in DGAT activity,
contributing to the DIO-associated elevation in DAG content
[27]. This is consistent with the observations of Somoza et al.,a s
they demonstrated an increase in intra-myocardial TAG content
at 4 weeks of DIO in C57BL/6J mice, followed by a reversion
to levels seen in lean mice after 8 weeks of DIO [35]. Contrary
to our previous observations, DIO also did not increase intra-
myocardial long chain acyl CoA levels [12,27]. It is important
to note that this observation is likely due to the high palmitate
concentration used in the perfusate (1.2 mM), which would
arbitrarily increase the palmitoyl CoA levels in perfused hearts
from low fat fed animals. As such, palmitoyl CoA levels
accounted for at least 70% of the total long chain acyl CoA
content measured in all groups, explaining why no increase in
long chain acyl CoA was observed in hearts following DIO in
this study. High levels of palmitoyl CoA may also account for a
lack of increase in intra-myocardial ceramide content, as
palmitoyl CoA is the substrate for SPT I-mediated ceramide
biosynthesis, and increased palmitoyl CoA levels in hearts from
lean mice may also arbitrarily increase their ceramide content,
masking any difference between lean and obese mice. However,
our previous studies looking at ceramide content in non-
perfused hearts from DIO mice also do not demonstrate an
increase in ceramide content [12,27]. Another factor that may
contribute to the lack of observed increase in intra-myocardial
ceramide content involves the young age of the mice in our
study, as a recent study by Sung et al. demonstrated no change
Figure 7. Myriocin treatment of DIO mice decreases intra-myocardial ceramide levels and prevents the accumulation of intra-
myocardial DAG. A: Intra-myocardial TAG, B: ceramide, C: long chain acyl CoA, and D: DAG levels in low fat fed and DIO mice treated with vehicle
control or myriocin. Values represent mean 6 SE (n=4–8). Differences were determined using a one-way ANOVA followed by Bonferroni post-hoc
analysis. *P,0.05, significantly different from vehicle control counterpart.
{P,0.05, significantly different from low fat fed counterpart.
doi:10.1371/journal.pone.0037703.g007
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37703Figure 8. Expression of enzymes involved in the regulation of fatty acid oxidation and hydroxyacyl CoA dehydrogenase activity in
db/db mice. Protein expression of A: PPARa, B: UCP3, C: CD36, and D: ACC in hearts from control and myriocin treated db/db mice. E: Hydroxyacyl
CoA dehydrogenase activity was similar in ventricular homogenates from control and myriocin treated db/db mice. Values represent mean 6 SE
(n=5–6).
doi:10.1371/journal.pone.0037703.g008
Figure 9. Myriocin treatment of db/db mice decreases intra-myocardial ceramide levels but has no effect on intra-myocardial DAG
content. A: Intra-myocardial ceramide, and B: DAG levels in db/db mice treated with vehicle control or myriocin. Values represent mean 6 SE (n=4–6).
Differences were determined using an unpaired Student’s two-tailed t-test. *P,0.05, significantly different from vehicle control counterpart.
doi:10.1371/journal.pone.0037703.g009
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significant increase if middle-aged mice were subjected to DIO
[34]. Interestingly, we did observe an increase in intra-
myocardial DAG content following DIO, which was prevented
in mice treated with myriocin. This finding is of particular
significance, as we have previously reported that intra-myocar-
dial DAG accumulation is more strongly associated with the
development of myocardial insulin resistance and impaired
glucose utilization versus the other lipid metabolites [27].
Whether the effect of myriocin on intra-myocardial DAG
content alone is responsible for improving myocardial glycolysis
rates in DIO mice has not been conclusively demonstrated in
this study, as myriocin treatment also resulted in a marked
reduction in intra-myocardial ceramide levels. However, in db/
db mice myriocin treatment reduced ceramide content without
altering DAG levels, and had no effect on insulin signaling,
supporting the premise that DAG is the more important lipid
metabolite in the heart affecting cardiac insulin sensitivity and
subsequent glucose utilization. Nevertheless, further character-
ization on the individual contributions of both ceramide and
DAG towards myocardial glucose utilization is required.
The improvement in myocardial glycolysis rates in DIO mice
treated with myriocin suggests an increase in myocardial glucose
uptake. However, because our protocol for measuring glycolysis
did not factor in the
3H radiolabel incorporating into glycogen, we
cannot conclude for certain that glucose uptake is increased in
hearts from DIO mice treated with myriocin. Despite this
limitation, insulin stimulated phosphorylation of Akt, a key
molecule involved in the insulin signaling cascade that regulates
glucose uptake [15,36,37,38], at serine 473 (indicative of increased
Akt activity) is increased in DIO mice treated with myriocin. It is
also important to note that while myriocin treated DIO mice
exhibited an improvement in myocardial glycolytic rates, they
were not normalized to normal values observed in lean mice,
illustrating that lipotoxic metabolites such as ceramide and DAG
are not the sole contributors to obesity-induced impairments in
myocardial glucose utilization. Indeed, inflammation and oxida-
tive stress may also impair myocardial glucose utilization [39,40],
and it is possible that while SPT I inhibition improves myocardial
lipid status, it has no impact on these other mechanisms that may
be activated in response to DIO.
Our previous findings have also demonstrated that DIO impairs
myocardial glucose oxidation rates [12,27], but due to the high
variability in glucose oxidation rates in hearts from low fat fed
animals, we did not report a decrease in this study, though there
was a very strong trend to a reduction in hearts from control
treated DIO mice. Further support for this observation in control
treated DIO mice is evident with the 44% reduction in myocardial
PDH activity, the rate-limiting enzyme for myocardial glucose
oxidation. Interestingly, PDH activity was not reduced in hearts
from myriocin treated DIO mice, once more suggesting that SPT I
inhibition improves obesity-induced impairments on myocardial
glucose utilization.
Although myriocin treatment improved myocardial glucose
utilization in DIO mice, we observed a slight increase in H
+
production in hearts from myriocin treated DIO mice, however
this did not reach statistical significance. In the aerobic setting
where we observed no difference in cardiac function between low
fat fed and DIO mice, as such, the consequences of this H
+ load
are likely minimal. Nonetheless, as even minor changes in
intracellular pH in the heart can significantly affect the recovery
of cardiac function during acute metabolic stresses such as
ischemia and reperfusion, the functional consequences of this
slight increase in H
+ production need to be further characterized
[16,17,41]. Interestingly, in the presence of elevated fatty acid
concentrations we have actually shown that treatment of the
mouse heart with insulin decreases the recovery of cardiac
function during ischemia/reperfusion, due to insulin increasing
H
+ production as a result of increasing glycolytic rates to a greater
extent than glucose oxidation rates [42]. Since myriocin treatment
can reverse obesity-induced insulin resistance and enhance energy
metabolism in mice [43,44], while also improving beta cell
function in obese rats [45], our future and ongoing studies are
addressing the potential role of SPT 1 in ischemic heart disease.
In summary, we demonstrate that DIO impairs myocardial
glucose utilization, which can be improved via SPT I inhibition.
The effect of SPT I inhibition was associated with a marked
reduction in intra-myocardial ceramide levels and prevented the
DIO-associated increase in intra-myocardial DAG content, both
of which likely contribute to the improved myocardial glucose
utilization. Although SPT I inhibition may represent a potential
novel target for the treatment of myocardial insulin resistance,
because glucose utilization was not restored to basal levels
observed in lean mice, further characterization of obesity-induced
myocardial insulin resistance and its associated mechanisms is
required.
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Table 5. Cardiac function and left ventricular wall
measurements in db/db mice treated with myriocin.
Study Group db/db control db/db myriocin
EF (%) 68.163.1 63.862.5
FS (%) 37.562.5 34.261.8
LV Mass (mg) 62.063.1 68.162.4
IVSd (mm) 0.6360.01 0.6860.02
LVIDd (mm) 3.7560.09 3.8360.11
LVPWd (mm) 0.6460.02 0.6560.02
IVSs (mm) 1.0560.03 1.0660.03
LVIDs (mm) 2.3560.12 2.5260.11
LVPWs (mm) 1.0160.03 1.0060.04
In vivo cardiac function and ventricular wall measurements were assessed via
echocardiography in isoflurane anesthetized db/db mice treated with vehicle
control or myriocin (n=5). Values represent means 6 SE. LVPW=left ventricular
posterior wall, LVID=left ventricular internal diameter, IVS=intraventricular
septum, d=diastole, s=systole.
doi:10.1371/journal.pone.0037703.t005
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